BCL2 and prostate cancer: Immunohistochemical analysis of bcl-2 protein levels in prostate tumors has revealed a correlation between the presence of bcI-2 protein and resistance to anti-androgen therapy.2 Taken together, these observations suggest that elevated levels of bcl-2 protein may contribute to the progression of prostate cancers to a metastatic and hormone-insensitive state characterized by poor responses to chemotherapy.